The report analyzes and
presents an overview of "
Psoriasis - Japan Drug Forecast and Market Analysis to 2024 "
worldwide.
Psoriasis
(PsO)
is an incurable genetic, systemic, inflammatory, and chronic skin
disorder with an overall prevalence of 2-3% worldwide. Specifically,
adult plaque psoriasis, the most common form of Psoriasis, is the
focus of this report. Although not life-threatening, Psoriasis causes
tremendous morbidity and personal angst for patients.
GlobalData projects the
Psoriasis market in 8MM to experience modest growth during the
forecast period at a CAGR of 7.26%. This growth will be driven
primarily by the highly anticipated arrivals of promising systemic
therapies- interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab
and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and
brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla
(apremilast). Nevertheless, looming patent expiries of high-grossing
branded drugs- especially TNF inhibitors, Humira, Enbrel and
Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and
Japan, along with rapid global developmentsof biosimilars are
expected to spread the growth throughout the different classes of
products, away from the branded TNF inhibitors which have
traditionally been the main driver of growth in the prior years.
Japan has not approved Amgens
Enbrel for the treatment of psoriasis, and we expect this to remain
so. However, Humira, Stelara, and more recently, Cosentyx are strong
choices as branded drugs in Japan. Humira and Stelara are both
expected to go off-patent in 2017 and 2021, respectively, while
Cosentyx is expected to remain patented well past the forecast period
end.
Download
Sample copy of this Report at
Scope
- Overview of Psoriasis
including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive
landscape.
- Detailed information on the
key drugs in Japan including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in Japan from 2014-2024.
- Analysis of the impact of key
events as well the drivers and restraints affecting Japan Psoriasis
market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for Psoriasis.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2014-2024 in Japan.
Table
of Contents
1.1
List of Tables
1.2
List of Figures
2
Introduction
2.1
Catalyst
2.2
Related Reports
2.3
Upcoming Related Reports
3
Disease Overview
3.1
Etiology and Pathophysiology
3.1.1
Etiology
3.1.2
Pathophysiology
3.2
Symptoms
4
Disease Management
4.1
Diagnosis and Treatment Overview
4.1.1
Diagnosis
4.1.2
Leading Prescribed Drugs and Treatment Guidelines
4.1.3
Clinical Practice
4.2
Japan
5
Competitive Assessment
5.1
Overview
5.2
Strategic Competitor Assessment
5.3
Product Profiles - Major Brands
5.3.1
Enbrel (Etanercept)
5.3.2
Humira (Adalimumab)
5.3.3
Remicade (Infliximab)
5.3.4
Stelara (ustekinumab)
5.3.5
Cosentyx (Secukinumab)
5.3.6
Otezla (Apremilast)
5.3.7
Taclonex and Enstilar (Calcipotriene and Betamethasone Dipropionate)
5.3.8
Methotrexate
5.3.9
Fumaderm (Fumaric Acid Esters)
5.3.10
Alzumab (itolizumab)
5.3.11
Other Therapeutic Drug Classes Used in Psoriasis
5.3.12
Non-pharmacological Therapy
6
Unmet Need and Opportunity
6.1
Overview
6.2
Limited Patient Access Due to Drug Reimbursement Pattern
6.2.1
Unmet Need
6.2.2
Gap Analysis
6.2.3
Opportunity
6.3
Improved Drug Safety and Efficacy Profiles
6.3.1
Unmet Need
6.3.2
Gap Analysis
6.3.3
Opportunity
6.4
Education and Treatment of Psychological Factors Accompanying
Psoriasis
6.4.1
Unmet Need
6.4.2
Gap Analysis
6.4.3
Opportunity
6.5
Physician Education About the Different Types of Psoriasis, not Just
Plaque Psoriasis
6.5.1
Unmet Need
6.5.2
Gap Analysis
6.5.3
Opportunity
7
Pipeline Assessment
7.1
Overview
7.2
Clinical Trial Mapping
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment